Over 450 Companies Accelerate Market Launches with Veeva RIM Solutions

More Than 450 Companies Drive Speed to Market with Veeva RIM

Veeva Systems (NYSE: VEEV) recently revealed that over 450 organizations, including 19 out of the top 20 biopharmaceutical companies, have embraced its Regulatory Information Management (RIM) solution on a unified platform. This widespread adoption signifies a major shift towards enhanced regulatory processes, enabling companies to streamline their operations significantly.

The Veeva RIM platform has been designed to meet the evolving needs of regulatory teams, offering advanced capabilities to improve connectivity with global health authorities. Due to strategic partnerships with companies like Accumulus Technologies and DNAnexus, Veeva has integrated its services with various health authority platforms, thus promoting operational efficiency and ensuring compliance. According to Marc Gabriel, Vice President of Regulatory at Veeva, ‘Regulatory teams are adopting new Veeva product innovations to continually improve efficiency and reduce cycle times.’

Companies utilizing Veeva RIM applications see enhanced workflow across all phases of the regulatory lifecycle. Notably, with the implementation of Veeva Submissions Publishing, over 85 organizations have benefited from continuous publishing, which minimizes rework and eliminates bottlenecks, effectively speeding up submission timelines.

As stated by Francisco Nogueira, CEO of Accumulus Technologies, their strategic collaboration will connect the Accumulus platform with Veeva RIM for improved interoperability. This integration allows for simultaneous sharing of information with a network of more than 70 regulatory agencies globally. Such advancements in operational connectivity empower mutual customers to deliver treatments to patients more promptly.

Furthermore, the integration of DNAnexus Trusted Regulatory Spaces (TRS) with Veeva RIM is set to enhance data-sharing capabilities among agencies, facilitating quicker regulatory approvals for products. The combination of these systems provides an end-to-end solution that not only accelerates time to market but also fosters collaboration with stakeholders throughout the regulatory process.

Veeva RIM functions as a cloud-based platform that consolidates global regulatory processes, forming part of the broader Veeva Development Cloud. This comprehensive technology foundation supports product development across clinical, quality, regulatory, and safety domains, reinforcing the connectivity and data management necessary in today’s rapidly changing regulatory landscape. Companies interested in exploring Veeva RIM further can visit veeva.com/eu/RIM.

In the context of life sciences, where the race against time is critical, Veeva’s innovative approach to RIM represents a paradigm shift that can significantly influence how regulatory teams manage and streamline processes. With a commitment to innovation and customer success, Veeva is making strides in establishing itself as a vital player in the life sciences sector, serving more than 1,500 clients ranging from prominent global biopharmaceutical firms to emerging biotech companies. Demonstrating a dedication to balance the interests of its stakeholders, Veeva operates as a Public Benefit Corporation, emphasizing its purpose beyond profit.

As we move forward, the implications of these integrated solutions on the pharmaceutical industry are vast. Companies harnessing the benefits of Veeva RIM and its advanced capabilities are better positioned to navigate the complexities of regulatory demands. This innovation not only contributes to enhancing the overall efficiency of the regulatory process but also optimizes the journey from development to market launch, ultimately benefiting patients who rely on these treatments.